Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Development and validation of serological markers for detecting recent Plasmodium vivax infection
Authors: Rhea J. Longley
Michael T. White
Eizo Takashima
Jessica Brewster
Masayuki Morita
Matthias Harbers
Thomas Obadia
Leanne J. Robinson
Fumie Matsuura
Zoe S.J. Liu
Connie S.N. Li-Wai-Suen
Wai Hong Tham
Julie Healer
Christele Huon
Chetan E. Chitnis
Wang Nguitragool
Wuelton Monteiro
Carla Proietti
Denise L. Doolan
Andre M. Siqueira
Xavier C. Ding
Iveth J. Gonzalez
James Kazura
Marcus Lacerda
Jetsumon Sattabongkot
Takafumi Tsuboi
Ivo Mueller
Foundation for Innovative New Diagnostics, Switzerland
Walter and Eliza Hall Institute of Medical Research
University of Melbourne
QIMR Berghofer Medical Research Institute
James Cook University, Australia
Mahidol University
CNRS Centre National de la Recherche Scientifique
CASE School of Medicine
Burnet Institute
Universidade do Estado do Amazonas
Ehime University
Institut Pasteur, Paris
Leônidas & Maria Deane Institute - Fiocruz Amazônia
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Instituto Nacional de Infectologia Evandro Chagas
CellFree Sciences Co., Ltd.
Keywords: Biochemistry, Genetics and Molecular Biology
Issue Date: 1-May-2020
Citation: Nature Medicine. Vol.26, No.5 (2020), 741-749
Abstract: © 2020, The Author(s), under exclusive licence to Springer Nature America, Inc. A major gap in the Plasmodium vivax elimination toolkit is the identification of individuals carrying clinically silent and undetectable liver-stage parasites, called hypnozoites. This study developed a panel of serological exposure markers capable of classifying individuals with recent P. vivax infections who have a high likelihood of harboring hypnozoites. We measured IgG antibody responses to 342 P. vivax proteins in longitudinal clinical cohorts conducted in Thailand and Brazil and identified candidate serological markers of exposure. Candidate markers were validated using samples from year-long observational cohorts conducted in Thailand, Brazil and the Solomon Islands and antibody responses to eight P. vivax proteins classified P. vivax infections in the previous 9 months with 80% sensitivity and specificity. Mathematical models demonstrate that a serological testing and treatment strategy could reduce P. vivax prevalence by 59–69%. These eight antibody responses can serve as a biomarker, identifying individuals who should be targeted with anti-hypnozoite therapy.
ISSN: 1546170X
Appears in Collections:Scopus 2020

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.